Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge Singapore; Memory Aging and Cognition Centre, National University Health System, Kent Ridge, Singapore.
Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore; Life Science Institute, Neurobiology Programme, Centre for Life Sciences, National University of Singapore, Singapore.
Free Radic Biol Med. 2021 Dec;177:201-211. doi: 10.1016/j.freeradbiomed.2021.10.019. Epub 2021 Oct 19.
Ergothioneine (ET) is a dietary amino-thione with strong antioxidant and cytoprotective properties and has possible therapeutic potential for neurodegenerative and vascular diseases. Decreased blood concentrations of ET have been found in patients with mild cognitive impairment, but its status in neurodegenerative and vascular dementias is currently unclear. To address this, a cross-sectional study was conducted on 496 participants, consisting of 88 with no cognitive impairment (NCI), 201 with cognitive impairment, no dementia (CIND) as well as 207 with dementia, of whom 160 have Alzheimer's Disease (AD) and 47 have vascular dementia. All subjects underwent blood-draw, neuropsychological assessments, as well as neuroimaging assessments of cerebrovascular diseases (CeVD) and brain atrophy. Plasma ET as well as its metabolite l-hercynine were measured using high sensitivity liquid chromatography tandem-mass spectrometry (LC-MS/MS). Plasma ET concentrations were lowest in dementia (p < 0.001 vs. NCI and CIND), with intermediate levels in CIND (p < 0.001 vs. NCI). A significant increase in l-hercynine to ET ratio was also observed in dementia (p < 0.01 vs. NCI). In multivariate models adjusted for demographic and vascular risk factors, lower levels of ET were significantly associated with dementia both with or without CeVD, while ET associations with CIND were significant only in the presence of CeVD. Furthermore, lower ET levels were also associated with white matter hyperintensities and brain atrophy markers (reduced global cortical thickness and hippocampal volumes). The incremental decreases in ET levels along the CIND-dementia clinical continuum suggest that low levels of ET are associated with disease severity and could be a potential biomarker for cognitive impairment. Deficiency of ET may contribute towards neurodegeneration- and CeVD-associated cognitive impairments, possibly via the exacerbation of oxidative stress in these conditions.
ergothioneine (ET) 是一种具有强抗氧化和细胞保护特性的膳食氨基酸,具有治疗神经退行性和血管疾病的潜在治疗作用。轻度认知障碍患者的血液 ET 浓度降低,但神经退行性和血管性痴呆患者的 ET 状况目前尚不清楚。为了解决这个问题,对 496 名参与者进行了横断面研究,包括 88 名无认知障碍 (NCI)、201 名认知障碍但无痴呆 (CIND) 以及 207 名痴呆患者,其中 160 名患有阿尔茨海默病 (AD),47 名患有血管性痴呆。所有受试者均接受了血液采集、神经心理学评估以及脑血管疾病 (CeVD) 和脑萎缩的神经影像学评估。使用高灵敏度液相色谱串联质谱法 (LC-MS/MS) 测量血浆 ET 及其代谢物 l-hercynine。血浆 ET 浓度在痴呆症中最低 (p < 0.001 与 NCI 和 CIND 相比),在 CIND 中浓度居中 (p < 0.001 与 NCI 相比)。还观察到痴呆症患者的 l-hercynine 与 ET 比值显著增加 (p < 0.01 与 NCI 相比)。在调整人口统计学和血管危险因素的多变量模型中,较低的 ET 水平与有无 CeVD 的痴呆症显著相关,而 ET 与 CIND 的关联仅在存在 CeVD 时才具有统计学意义。此外,较低的 ET 水平也与白质高信号和脑萎缩标志物相关 (降低的全脑皮质厚度和海马体积)。CIND-痴呆症临床连续体中 ET 水平的逐渐降低表明,低水平的 ET 与疾病严重程度相关,可能是认知障碍的潜在生物标志物。ET 的缺乏可能导致与神经退行性变和 CeVD 相关的认知障碍,可能是通过在这些情况下加剧氧化应激。